Meeting
2023 ASCO Annual Meeting
Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with early-stage, triple-negative breast cancer.
Authors
Vishnu Venkatesh
University of Texas Southwestern Medical Center, Dallas, TX
Vishnu Venkatesh , Christine Yen , Ray Zhang , Anjali Rao , Alvin Chandra , Vlad Zaha , Srilakshmi Vallabhaneni , Kathleen W Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2607)
DOI
10.1200/JCO.2023.41.16_suppl.2607
Abstract #
2607
Poster Bd #
449
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
First Author: Nicholas Mai
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Annual Meeting
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.
First Author: Heather L. McArthur